EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysis

Agata Suleja, Deborah Bret, Marcin Miszczyk, Wen Dong, Xi Zhou, Ekaterina Laukhtina, Bernhard Englinger, Paweł Rajwa, Pierre I Karakiewicz, Vérane Achard, Bernadett Szabados, Eva Compérat und 3 weitere

World Journal of Urology · 14.11.2026 · 44 (1)

DOI: 10.1007/s00345-026-06868-2 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift World Journal of Urology, online erschienen am 14.11.2026. Verfasst von Agata Suleja und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Aust…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Molecular Targeted Therapy. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

HER2-targeted antibody–drug conjugates were recently approved in China for treatment of advanced or metastatic urothelial carcinoma (UC). We summarise emerging evidence supporting use of HER2-targeted regimens in patients with localized disease.

Methods

We searched MEDLINE, Embase, Web of Science, CENTRAL through March 29, 2026, and SinoMed, Wanfang and CNKI through October 14, 2025 to identify studies evaluating HER2-targeted therapies, in patients with localized UC. Random-effects meta-analyses pooled response rates, including pathological complete response (pCR). Clinical complete response (cCR) was stratified by response definition. Heterogeneity was assessed using Cochrane's Q test. Risk-of-bias (RoB) was assessed using ROBINS-I tool. The study was registered prospectively (CRD420250650326).

Results

Thirty-three studies comprising 970 patients were included (17 prospective); 30 tested disitamab vedotin (DV). In 13 studies testing DV-containing regimens as neoadjuvant therapy, the pooled pCR rate was 48% (95% CI 39–58%, N = 398; 54% among surgery-evaluable patients). Evidence was insufficient to establish an association between HER2 expression and pCR (risk ratio [RR] 0.82, 95% CI 0.52–1.29; p = 0.38; N = 72). In bladder-sparing studies, cCR was 65% (95% CI 44–82%) with definitions requiring complete absence of residual tumor and 54% (95% CI 41–67%) with definitions permitting residual Ta/Tis disease. Among included trials using DV, rate of grade ≥3 adverse events did not exceed 35% and was lower than that reported in studies evaluating other HER2-targeted agents. Major RoB concerns regarded outcome measurement as none of included trials was blinded.

Conclusions

DV-containing regimens show promising activity as neoadjuvant therapy in patients with bladder cancer. Current evidence is insufficient to establish an association between HER2 expression and response. Emerging data indicate possible role in bladder-sparing setting with low rates of toxicity and no G5 safety signals, although heterogeneous cCR definitions limit interpretation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesCarcinoma, Transitional CellUrinary Bladder NeoplasmsMolecular Targeted TherapyImmunoconjugatesHumansTreatment OutcomePathologic Complete ResponseAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Antibody–drug conjugateDisitamab vedotinHER2Neoadjuvant therapyUrothelial carcinoma

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanImmunoconjugatesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Collegium Medicum, WSB University, Dąbrowa Górnicza, Poland.
  • Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, China.
  • Center for Cancer Research, Medical University of Vienna, Vienna, Austria.
  • Division of Surgery and Interventional Sciences, University College London, University College London Hospital, London, UK.
  • Department of Urology, Medical University of Silesia, Zabrze, Poland.

Förderung

  • Medical University of Vienna

Zitieren

APA

Suleja, A., Bret, D., Miszczyk, M., Dong, W., Zhou, X., Laukhtina, E., Englinger, B., Rajwa, P., Karakiewicz, P. I., Achard, V., Szabados, B., Compérat, E., Rosenberg, J. E., Zhou, P., & Shariat, S. F. (2026). Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysis. World Journal of Urology, 44(1). https://doi.org/10.1007/s00345-026-06868-2

Vancouver

Suleja A, Bret D, Miszczyk M, Dong W, Zhou X, Laukhtina E, et al. Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysis. World Journal of Urology. 2026;44(1). doi:10.1007/s00345-026-06868-2

BibTeX
@article{Suleja2026,
  author = {Suleja, Agata and Bret, Deborah and Miszczyk, Marcin and Dong, Wen and Zhou, Xi and Laukhtina, Ekaterina and Englinger, Bernhard and Rajwa, Paweł and Karakiewicz, Pierre I and Achard, Vérane and Szabados, Bernadett and Compérat, Eva and Rosenberg, Jonathan E and Zhou, Pixiao and Shariat, Shahrokh F},
  title = {Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysis},
  journal = {World Journal of Urology},
  year = {2026},
  volume = {44},
  number = {1},
  doi = {10.1007/s00345-026-06868-2}
}
Kostenlos starten →